Next Phase Newsletter

A venture capital firm was founded in 2014 and is based in Palo Alto, CA. The firm invests across multiple industries – within healthcare, the firm is interested in AI in healthcare and medical devices. The firm manages 3 funds right now, and the latest fund closed in 2022. The firm typically invests $1M-$2M initial check per company, and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their CXO network which includes over 30 executives from Fortune 1000 companies. 

The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage. 

The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A life sciences focused venture fund with global vision and reach is dedicated to advancing innovative medicines. It has raised multiple USD funds from renowned institutional funds as well as strategic investors and has investments in more than 30 private companies and several public companies, one third of which it has seeded or incubated. The firm’s highly experienced investment Partners have greater than 100 years of combined investing experience, and along with their Venture Partners and advisors have collective experience in emerging and established biotech, multinational pharmaceutical companies, academic institutions, and key regulatory agencies. The firm has a strong preference for leading investments and play an active role in their portfolio companies supporting their success. The firm’s global team resides in New York, Boston, Silicon Valley, Singapore, and Shanghai. 
 
The firm invests in disease areas of high unmet need and invests across the sub-sectors of life sciences, across geography and development stage. The firm leverages a unique cross-functional talent base to create value from company formation all the way to public market investing. 
 
The firm is an active lead investor, and the firm has a board seat in most of its investments. It deploys its unique cross functional experts and assists portfolio companies with capital markets strategies, business development, clinical development, regulatory and commercial strategies. Outside of the board requirement, the firm seeks to back management teams with passion and capability in advancing the company’s technology. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Headquartered in Hong Kong, with offices in the US, an international asset management hub is actively investing in technology and healthcare. The firm focuses on early-stage and expansion opportunities, and can invest in both equity and debt. It typically participates in Series A to Series B rounds, with check sizes ranging from $1M to $50M. The firm primarily focuses on the US and Europe and is particularly interested in companies aiming to expand into Asian markets. The firm has partnerships with manufacturing, CRO, and distribution channels in China and is open to leveraging these resources for its portfolio companies. The firm is open to both leading and co-investing. 
 
The firm primarily considers opportunities in therapeutics, medical devices, and healthtech. For therapeutics, the firm prefers companies/assets in the post-IND phase or those generating clinical data. For medical devices, the firm is open to all classes: for Class I devices, the firm prefers products that have already received approval; for Class II and Class III devices, it prefers mid to late-stage products with CE/FDA approval. For healthtech companies, the firm prefers those already generating revenue. The firm focuses on indications with large market potential, particularly in the US and China. 
 
The firm does not have specific requirements for a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A life-sciences focused venture capital firm is currently making investments into US-based companies. The firm primarily makes equity investment into seed and early stage rounds ranging from $250,000 to $1 million initially and up to $2 million over the lifetime of the investment.  The firm could make as many as 3 new investments over the next 6-9 months. 
 
The firm is looking for U.S. companies in sectors of Therapeutics, Diagnostics, Medical Devices, Life Science Tools and digital health. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in early-stage companies including pre-clinical stage companies with some supporting in-animal data, although it is not a requirement. 
 
The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm that manages innovative venture capital funds and is based in San Diego, California. The firm invests in early, growth, and expansion-stage technology and life science companies. The firm principally invests in early and growth-stage investments in Series A, B, and C preferred equity rounds with other top-tier institutional and corporate investors. The investment size is variable and dependent on the company’s capitalization plan and future capital requirements. The firm currently focuses its investment activities in parts of the western USA that are under-served by venture capital. The firm is actively seeking institutional investment limited partners and new investment opportunities. 
 
In the Life Sciences area, the firm seeks to invest in medical device, product, diagnostics, specialty pharma, and healthcare IT.  The firm is opportunistic in terms of sub-sectors and indications.  The firm generally seeks clinical stage therapeutics that are at least Phase II, and diagnostics and medical devices that are very close to or with FDA approval. 
 
The firm is led by a seasoned VC with a track record of investing.  The firm generally co-invests with other top-tier institutional and corporate investors, and will work with companies to help them organize an investment syndicate. The firm seeks investment opportunities in rapidly growing companies with world-class products and solutions that address major market needs; along with talented leadership, management teams, and boards with deep industry experience and track records of success. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global healthcare company that specializes in plasma-related medicines has a global presence in the US, Europe, and Asia. The firm’s external innovation arm seeks to partner with early-stage companies developing therapeutic assets that strategically align with the firm’s focus areas. The group is science-focused and strategically invests in the corporation’s long-term goal of developing pipelines in biotech beyond plasma-related medicines. The group primarily makes equity investments but is open to different structures such as co-development, licensing, and potentially acquisitions. The group often co-invests/syndicates with other investors and typically does not require a board seat. The group is open to considering global opportunities with a focus on the US and Europe. 

The group is focused on therapeutics and is not interested in diagnostics or other sectors. The group seeks strategic alignments within the parent company’s pharma business, which focuses on immunology, infectious diseases, pulmonology, and hematology. The group is particularly interested in biologics due to their expertise in this class of assets and is open to considering other classes of assets such as small molecules, cell and gene therapy (platform), mRNA therapies, etc. The group is also open to considering orphan diseases as well. In terms of phases of development, the group is interested in pre-clinical to early clinical phases. 

The group does not have any specific requirements for the company’s management team. The group acts as an active investor and is open to working with portfolio companies with their in-house expertise and leveraging the firm’s manufacturing capabilities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A digital healthcare-focused seed fund that was founded in 2015 typically acts as the lead investor in a priced equity round. The firm’s team is made up of three partners and has collectively invested in more than a dozen digital health companies as individual investors. The fund currently focuses on opportunities across the United States, with a target investment in the $500,000 range. 

The firm seeks to fund companies working in the digital health space, including health data management systems, patient-physician interface, cloud computing, and software-enabled devices. 

The firm looks for teams that have some healthcare experience in senior management. The firm prefers a strong founding team, possessing varied skills that include technical expertise, sales, operational and marketing experience in senior leadership. After investment, the firm actively advise portfolio companies in various ways, including helping with introductions to health system customers, building teams and advising on operations and management. As such the firm will usually hold a seat on the board along with the founders. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.